Oregovomab is a murine monoclonal antibody
Oregovomab is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer in the phase 3 FLORA-5 trial. (Credit: Hush Naidoo Jade Photography on Unsplash)
CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa (MENA) region.
“We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations,” said Michael Na, CEO of CanariaBio.
Oregovomab is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer in the phase 3 FLORA-5 trial. In Phase 2, the addition of oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027). The hazard ratio of overall survival was 0.35.
Source: Company Press Release